Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT02886585 |
TitlePembrolizumab In Central Nervous System Metastases | Phase
Phase 2
|
Date Added 2016-09-01 |
Location
Massachusetts, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03030378 |
TitlePembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors | Phase
Phase 1
|
Date Added 2017-01-25 |
Location
California, United States
Colorado, United States Connecticut, United States Florida, United States Georgia, United States Iowa, United States Maryland, United States Massachusetts, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Edodekin alfa, Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05201612 |
TitlePembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). | Phase
Phase 2
|
Date Added 2022-01-21 |
Location
Spain
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Unknown status
|
Drugs
Olaparib, Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05333809 |
TitlePembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-04-19 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Disitamab vedotin, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT05491083 |
TitlePembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | Phase
Phase 1
|
Date Added 2022-08-08 |
Location |
Prior IO Allowed No |
CRC-directed No |
Status
Not yet recruiting
|
Drugs
Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03844750 |
TitlePembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery | Phase
Phase 2
|
Date Added 2019-02-18 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Vactosertib, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT03239145 |
TitlePembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Phase
Phase 1
|
Date Added 2017-08-03 |
Location
Massachusetts, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Trebananib |
Tags
MSS/ MMRp
|
| NCT ID NCT03638297 |
TitlePD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | Phase
Phase 2
|
Date Added 2018-08-20 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
PD-1 antibody + cox inhibitor |
Tags
MSI-H/ MMRd
|
| NCT ID NCT02215889 |
TitlePartial Liver Segment 2/3 Transplantation Study | Phase
Phase 1
|
Date Added 2014-08-13 |
Location
Norway
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06764680 |
TitleOral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer | Phase
Phase 2
|
Date Added 2025-01-08 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
